Alumis (ALMS) Cash from Financing Activities (2023 - 2025)
Alumis (ALMS) posted quarterly Cash from Financing Activities of $1.3 million for Q4 2025, up 26260.0% year-over-year from N/an in Q4 2024, and up 26260.0% quarter-over-quarter from $5000.0 in Q4 2024.
Alumis (ALMS) Cash from Financing Activities (2023 - 2025) Analysis & Trends
Alumis (ALMS) has reported Cash from Financing Activities for 3 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 26260.0% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $236.5 million (down 51.97% YoY), while the FY2025 annual figure was $2.1 million, down 99.58% from the prior year.
- Cash from Financing Activities climbed to $1.3 million in Q4 2025 per ALMS's latest filing, from $5000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $235.2 million in Q3 2024 and bottomed at $5000.0 in Q4 2024.
- Historically, Cash from Financing Activities has averaged $74.8 million across 3 years, with a median of $29.7 million in 2023.
- On a YoY basis, Cash from Financing Activities climbed as much as 500221.28% in 2024 and fell as far as 99.98% in 2024.
- Alumis' Cash from Financing Activities stood at $29.7 million in 2023, then tumbled by 99.98% to $5000.0 in 2024, then surged by 26260.0% to $1.3 million in 2025.
- Business Quant data shows ALMS's Cash from Financing Activities at $1.3 million in Q4 2025, $5000.0 in Q4 2024, and $235.2 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.32 Mn |
| Dec 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 235.15 Mn |
| Sep 30, 2024 | 235.15 Mn |
| Jun 30, 2024 | 128.06 Mn |
| Jun 30, 2024 | 128.06 Mn |
| Mar 31, 2024 | 129.15 Mn |
| Mar 31, 2024 | 129.15 Mn |
| Dec 31, 2023 | 29.72 Mn |
| Dec 31, 2023 | 29.72 Mn |
| Sep 30, 2023 | 47,000.00 |
| Sep 30, 2023 | 47,000.00 |